Clinical Trial

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not controlled by Metformin with or without DPP-4 inhibitors. Additionally, the study will compare changes in other metabolic or cardiovascular risk factors, such as triglycerides, high density lipoprotein cholesterol (HDLc), uric acid, blood pressure, and inflammatory markers, between the two drugs.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-03.
Trial Details
NCT Number NCT06399835
Lead Sponsor Seoul National University Bundang Hospital
Collaborators: Daewoong Pharmaceutical Co. LTD.
Conditions Type 2 Diabetes
Enrollment 120 participants
Start Date 2024-02-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05